EUVIMEDEUVIMED entdecken
Crossref

Real world, retrospective experience of glucagon-like peptide-1 receptor agonists in kidney transplant recipients: A single-center case series

Priyamvada Singh, Melissa McGowan, Lauren Von Stein, Johanna Papanikolla, Annelise Nolan, Hannah Lingren, Noah Jagielski, Navdeep Singh, Shumei Meng, Todd Pesavento

Clinical Nephrology · 01.05.2026 · 105 (5) · 318-324

DOI: 10.5414/cn111893 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Nephrology, erschienen am 01.05.2026. Verfasst von Priyamvada Singh und 9 weiteren Autor:innen. Hauptthemen laut MEDLINE: Kidney Transplantation, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Hypoglycemic Agents.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We conducted a retrospective chart review of adult kidney transplant recipients (KTxR) with type 2 diabetes treated with a glucagon-like peptide-1 receptor agonist (GLP-1RA). A total of 211, 207, 161, and 92 KTxR were followed for 6, 12, 36, and 60 months, respectively. Over 5 years, we observed statistically significant reductions in the primary endpoints of weight, HbA1c, and major adverse cardiovascular events (MACE). The mean weight reduction was as follows: 1.17 kg at 6 months (p < 0.006), 1.2 kg at 12 months (p < 0.03), 3.7 kg at 36 months (p < 0.0001), and 4.1 kg at 60 months (p = 0.001) compared to baseline. The HbA1c levels showed reductions of 0.6 mmol/mol at 6 months (p < 0.0001), 0.5 mmol/mol at 12 months (p = 0.0004), 0.3 mmol/mol at 36 months (p = 0.04), and 0.35 mmol/mol at 60 months (p = 0.35). MACE rates fell from 45.5% at GLP-1RA initiation to 18.9% during follow-up (OR 3.6 (2.3 - 5.6), p < 0.0001). Insulin requirements decreased from 50 to 27 units over 5 years. Kidney function reduces over time in KTx, likely secondary to hemodynamic or vascular-mediated risk factors, chronic immunosuppressive agents, treatment for rejections, and solitary transplanted kidney. In our study, estimated glomerular filtration rate (eGFR) not only stayed stable but also showed a trend towards improvement (eGFR improved from 50 to 53 mL/min/1.73m2). Further prospective randomized trials are needed to assess GLP-1RA efficacy and safety in KTxR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationGlucagon-Like Peptide-1 Receptor AgonistsDiabetes Mellitus, Type 2Hypoglycemic AgentsHumansRetrospective StudiesFemaleMiddle AgedGlycated HemoglobinMaleTreatment OutcomeGlucagon-Like Peptide-1 ReceptorTime FactorsAgedCardiovascular DiseasesExenatideAdultPeptidesVenoms

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsGlycated Hemoglobinhemoglobin A1c protein, humanGlucagon-Like Peptide-1 ReceptorGLP1R protein, humanExenatidePeptidesVenoms

Zitieren

APA

Singh, P., McGowan, M., Von Stein, L., Papanikolla, J., Nolan, A., Lingren, H., Jagielski, N., Singh, N., Meng, S., & Pesavento, T. (2026). Real world, retrospective experience of glucagon-like peptide-1 receptor agonists in kidney transplant recipients: A single-center case series. Clinical Nephrology, 105(5), 318-324. https://doi.org/10.5414/cn111893

Vancouver

Singh P, McGowan M, Von Stein L, Papanikolla J, Nolan A, Lingren H, et al. Real world, retrospective experience of glucagon-like peptide-1 receptor agonists in kidney transplant recipients: A single-center case series. Clinical Nephrology. 2026;105(5):318-324. doi:10.5414/cn111893

BibTeX
@article{Singh2026,
  author = {Singh, Priyamvada and McGowan, Melissa and Von Stein, Lauren and Papanikolla, Johanna and Nolan, Annelise and Lingren, Hannah and Jagielski, Noah and Singh, Navdeep and Meng, Shumei and Pesavento, Todd},
  title = {Real world, retrospective experience of glucagon-like peptide-1 receptor agonists in kidney transplant recipients: A single-center case series},
  journal = {Clinical Nephrology},
  year = {2026},
  volume = {105},
  number = {5},
  pages = {318--324},
  doi = {10.5414/cn111893}
}
Kostenlos starten →